Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Nov. 23 to 25, 2020. This …
Development of an international core domain set for medium, large and giant congenital melanocytic nevi as a first step towards a core outcome set for clinical practice and research.
Medium, large and giant congenital melanocytic nevi (CMN) can impose a psychosocial burden on patients and families, and are associated with increased risk of developing melanoma or neurological symptoms. Lack …
U.S. COVID-19 Vaccine Distribution Could Begin in Mid-December
Vaccine appears 95 percent effective at preventing mild-to-severe COVID-19, according to the manufacturers
Burden, risk factors and infectious complications of cellulitis and erysipelas in United States adults and children in the emergency department setting.
Little is known about the utilization and burden of emergency department (ED) visits for cellulitis/erysipelas in the United States.To determine the prevalence, risk factors, complications and cost of emergency care …
Development of a Core Outcome Set for Cutaneous Squamous Cell Carcinoma Trials: Identification of Core Domains and Outcomes.
The lack of uniformity in the outcomes reported in clinical studies of the treatment of cutaneous squamous cell carcinoma (cSCC) complicates efforts to compare treatment effectiveness across trials.To develop a …
Predictors of Satisfaction With RYGB Over Seven Years Identified
And, physical activity associated with improvements in depression and mental and physical HRQoL after RYGB
AI Algorithm Can Detect COVID-19 on Chest X-Rays
Accuracy of 82 percent achieved with DeepCOVID-XR compared with 81 percent for consensus of five thoracic radiologists
Job Changes Increasingly Common Among U.S. Radiologists
Practice separation most common among early- and late-career radiologists, general radiologists
Fauci Calls for Americans to Pull Together, Says ‘Help Is on the Way’
Anthony Fauci, M.D., spoke with HD Live! about the safety and efficacy of a COVID-19 vaccine and doubling down on efforts to stop the surge in cases